FDA provides supplemental approval for Spravato (esketamine) CIII nasal spray, for adults living with major depressive disorder – Johnson & Johnson
Johnson & Johnson announced the FDA approval of a supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray, making this innovative treatment the first and only… read more.